Journal article · 2019 · Open access
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania
Malaria Journal, 18(1), 88 · Published 21 March 2019 · DOI 10.1186/s12936-019-2730-1
In brief
“Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania” is a 2019 journal article by Deus S. Ishengoma and 23 co-authors, published in Malaria Journal. OpenAlex counts 83 citations as of 19 November 2026, which puts it in the top 7% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Malaria Journal.
- Citations
- 83
- Most cited in
- 2024 (18)
- Field-weighted impact
- 7.48
- References
- 45
- Authors
- 24
Abstract
BACKGROUND: The World Health Organization recommends regular therapeutic efficacy studies (TES) to monitor the performance of first and second-line anti-malarials. In 2016, efficacy and safety of artemether-lumefantrine (AL) for the treatment of uncomplicated falciparum malaria were assessed through a TES conducted between April and October 2016 at four sentinel sites of Kibaha, Mkuzi, Mlimba, and Ujiji in Tanzania. The study also assessed molecular markers of artemisinin and lumefantrine (partner drug) resistance. METHODS: Eligible patients were enrolled at the four sites, treated with standard doses of AL, and monitored for 28 days with clinical and laboratory assessments. The main outcomes were PCR corrected cure rates, day 3 positivity rates, safety of AL, and prevalence of single nucleotide polymorphisms in Plasmodium falciparum kelch 13 (Pfk13) (codon positions: 440-600) and P. falciparum multi-drug resistance 1 (Pfmdr1) genes (codons: N86Y, Y184F and D1246Y), markers of artemisinin and lumefantrine resistance, respectively. RESULTS: Of 344 patients enrolled, three withdrew, six were lost to follow-up; and results were analysed for 335 (97.4%) patients. Two patients had treatment failure (one early treatment failure and one recrudescent infection) after PCR correction, yielding an adequate clinical and parasitological response of > 98%. Day 3 positivity rates ranged from 0 to 5.7%. Common adverse events included cough, abdominal pain, vomiting, and diarrhoea. Two patients had serious adverse events; one died after the first dose of AL and another required hospitalization after the second dose of AL (on day 0) but recovered completely. Of 344 samples collected at enrolment (day 0), 92.7% and 100% were successfully sequenced for Pfk13 and Pfmdr1 genes, respectively. Six (1.9%) had non-synonymous mutations in Pfk13, none of which had been previously associated with artemisinin resistance. For Pfmdr1, the NFD haplotype (codons N86, 184F and D1246) was detected in 134 (39.0%) samples; ranging from 33.0% in Mlimba to 45.5% at Mkuzi. The difference among the four sites was not significant (p = 0.578). All samples had a single copy of the Pfmdr1 gene. CONCLUSION: The study indicated high efficacy of AL and the safety profile was consistent with previous reports. There were no known artemisinin-resistance Pfk13 mutations, but there was a high prevalence of a Pfmdr1 haplotype associated with reduced sensitivity to lumefantrine (but no reduced efficacy was observed in the subjects). Continued TES and monitoring of markers of resistance to artemisinin and partner drugs is critical for early detection of resistant parasites and to inform evidence-based malaria treatment policies. Trial Registration ClinicalTrials.gov NCT03387631.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ishengoma, D. S., Mandara, C. I., Francis, F. T., Talundzic, E., Lucchi, N. W., Ngasala, B., Kabanywanyi, A. M., Mahende, M. K., Kamugisha, E., Kavishe, R. A., Muro, F. J., Mohamed, A., Mandike, R., Mkude, S., Chacky, F., Paxton, L. A., Greer, G. R., Kitojo, C. A., Njau, R., . . . Udhayakumar, V. (2019). Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malaria Journal, 18(1), 88. https://doi.org/10.1186/s12936-019-2730-1
MLA 9
Ishengoma, Deus S., et al. “Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.” Malaria Journal, vol. 18, no. 1, 2019, p. 88. https://doi.org/10.1186/s12936-019-2730-1.
Chicago
Ishengoma, Deus S., Celine I. Mandara, Filbert T. Francis, Eldin Talundzic, Naomi W. Lucchi, Billy Ngasala, Abdunoor M. Kabanywanyi, et al. 2019. “Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.” Malaria Journal 18 (1): 88. https://doi.org/10.1186/s12936-019-2730-1.
Harvard
Ishengoma, D. S. et al. (2019) ‘Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania’, Malaria Journal, 18(1), p. 88. doi:10.1186/s12936-019-2730-1.
IEEE
D. S. Ishengoma et al., “Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania,” Malaria Journal, vol. 18, no. 1, p. 88, 2019, doi: 10.1186/s12936-019-2730-1.
BibTeX
@article{ishengoma2019efficacy,
title = {{Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania}},
author = {Ishengoma, Deus S. and Mandara, Celine I. and Francis, Filbert T. and Talundzic, Eldin and Lucchi, Naomi W. and Ngasala, Billy and Kabanywanyi, Abdunoor M. and Mahende, Muhidin Kassim and Kamugisha, Erasmus and Kavishe, Reginald Adolph and Muro, Florida Joseph and Mohamed, Ally and Mandike, Renata and Mkude, Sigsbert and Chacky, Frank and Paxton, Lynn A. and Greer, George R. and Kitojo, Chonge A. and Njau, Ritha and Martin, Troy M. and Venkatesan, Meera and Warsame, Marian and Halsey, Eric S. and Udhayakumar, Venkatachalam},
journal = {Malaria Journal},
year = {2019},
volume = {18},
number = {1},
pages = {88},
doi = {10.1186/s12936-019-2730-1},
url = {https://doi.org/10.1186/s12936-019-2730-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 2 | |
| 2020 | 11 | |
| 2021 | 13 | |
| 2022 | 11 | |
| 2023 | 14 | |
| 2024 | 18 | |
| 2025 | 8 | |
| 2026 | 6 |
Its field-weighted citation impact is 7.48: it has been cited 7.48 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- artemether-lumefantrine
- uncomplicated falciparum malaria
- treatment efficacy
- drug safety
- artemisinin resistance
- lumefantrine resistance
- pfk13 mutations
- Plasmodium falciparum
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ishengoma, D. S., Mandara, C. I., Francis, F. T., Talundzic, E., Lucchi, N. W., Ngasala, B., Kabanywanyi, A. M., Mahende, M. K., Kamugisha, E., Kavishe, R. A., Muro, F. J., Mohamed, A., Mandike, R., Mkude, S., Chacky, F., Paxton, L. A., Greer, G. R., Kitojo, C. A., Njau, R., . . . Udhayakumar, V. (2019). Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malaria Journal, 18(1), 88. https://doi.org/10.1186/s12936-019-2730-1
How many times has this paper been cited?
83 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Malaria Journal: sign in and open the PDF from this page.
Who wrote this paper?
Deus S. Ishengoma, Celine I. Mandara, Filbert T. Francis, Eldin Talundzic, Naomi W. Lucchi, Billy Ngasala, Abdunoor M. Kabanywanyi, Muhidin Kassim Mahende, Erasmus Kamugisha, Reginald Adolph Kavishe, Florida Joseph Muro, Ally Mohamed and 12 more.
What is the DOI of this paper?
10.1186/s12936-019-2730-1, permanently at https://doi.org/10.1186/s12936-019-2730-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.